India, May 20 -- image credit- shutterstock

Mumbai-based pharma major Lupin has announced its plan to use Honeywell's Solstice(R) Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the development of next-generation inhalers.

Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions.

Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to...